Horváth Barbara, Demeter Judit, Eros Nóra, Hársing Judit, Csomor Judit, Matolcsy András, Bottlik Gyula, Gyori Gabriella, Marschalkó Márta, Kárpáti Sarolta
Department of Dermatology, Venerology, and Dermatooncology, Semmelweis University, Budapest, Hungary.
J Am Acad Dermatol. 2009 Nov;61(5):885-8. doi: 10.1016/j.jaad.2008.12.045. Epub 2009 Jul 25.
Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system. Most cases are of B-cell origin; T-cell phenotype is extremely rare. Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms. The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab. We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.
血管内淋巴瘤是一种罕见的、侵袭性很强的结外非霍奇金淋巴瘤，最常累及皮肤和中枢神经系统。大多数病例起源于B细胞；T细胞表型极为罕见。恶性细胞在毛细血管、小动脉、小静脉和小动脉的管腔内增殖；血管闭塞导致临床症状和体征。自抗CD20单克隆抗体利妥昔单抗问世以来，这种高级别B细胞淋巴瘤的预后有所改善。我们报告一例成功接受利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松龙治疗的B细胞血管内淋巴瘤病例。
